Exhibit 1

 

JOINT FILING AGREEMENT

 

The undersigned hereby agree that this Statement on Schedule 13D, dated January 17, 2025 (the “Schedule 13D”), with respect to the common stock, par value $0.01 per share, of Outlook Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Joint Filing Agreement (this “Agreement”) shall be included as an Exhibit to the Schedule 13D. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 22nd day of January, 2025.

 

Dated: January 22, 2025 GMS Ventures and Investments
     
  By: /s/ Lawrence A. Kenyon
    Name: Lawrence A. Kenyon
    Title: Attorney-in-Fact
     
  Ghiath M. Sukhtian
     
  By: /s/ Lawrence A. Kenyon
    Name: Lawrence A. Kenyon
    Title: Attorney-in-Fact

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
Outlook Therapeutics (NASDAQ:OTLK)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Outlook Therapeutics 차트를 더 보려면 여기를 클릭.
Outlook Therapeutics (NASDAQ:OTLK)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Outlook Therapeutics 차트를 더 보려면 여기를 클릭.